AzTrials
AzTrials

Tobacco Use DisorderPhase 2NCT03337113

Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers

A Phase 2 study testing Working Memory Training and repetitive Transcranial Magnetic Stimulation in people with Tobacco Use Disorder, run by Kent State University at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Smoking remains the leading cause of preventable death in the United States, and current first-line treatments leave the majority of tobacco dependent individuals unable to quit. The inability to quit despite motivation to do so, is thought to result in part, from self-control failure. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Tobacco Use Disorder
What is being tested?
Working Memory Training and repetitive Transcranial Magnetic Stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
2 sitesUnited States
Study dates
5 Mar 2018to 31 Jan 2021
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • meet safety guidelines for application of rTMS
  • be 18-60 years of age
  • have smoked cigarettes regularly for at least one year
  • currently smoke at least 10 cigarettes per day
  • have a carbon monoxide (CO) level >10 ppm
  • currently use no other nicotine products regularly

Who cannot join

  • meet criteria for current alcohol or substance dependence
  • have a current affective disorder (depression, dysthymia, or mania) or psychotic symptoms
  • are currently pregnant or lactating, or intend to become pregnant
  • have a health condition for which rTMS is contraindicated

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Brown University

    Providence, Rhode Island, 02906

  • Butler Hospital

    Providence, Rhode Island, 02906

Other trials in United States

About this study

Official title: Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers: 2x2 Factorial Study

Smoking remains the leading cause of preventable death in the United States, and current first-line treatments leave the majority of tobacco dependent individuals unable to quit. The inability to quit despite motivation to do so, is thought to result in part, from self-control failure. Working memory (WM) deficits contribute to imbalanced self-control and allow automatic impulses to drive behavior. Thus, WM plays a critical role in addictive behavior, and is particularly relevant to smoking. Indeed, a strong link between WM and smoking has been established in the literature; most notably, degree of WM impairment and deficits in activation in associated brain regions predict time to relapse, and WM moderates the relationship between craving and relapse. Given these insights, researchers have been examining interventions that may target WM including WM training (WMT) and repetitive Transcranial Magnetic Stimulation (rTMS). WMT involves taxing this executive function repeatedly over time and has shown positive preliminary results in improving measures of self-control and reducing consumption of addictive substances. Similarly, rTMS, a non-invasive brain stimulation procedure that stimulates neuronal tissues and increases cortical excitability, has been shown to increase WM capacity and reduce craving and consumption of several addictive substances including nicotine. While these interventions have demonstrated initial promise in affecting addictive behaviors, the magnitude and durability of their effects may be limited. Recently, researchers have posited - but not yet empirically tested - that WMT administered in combination with rTMS may result in an additive or supra-additive effect in treating addictive processes. This is highly significant; the clinical utility of rTMS over current first line treatments may be limited if factors with potential to enhance its effectiveness are not examined. Given these recent advances in the literature, the primary objective of the proposed study is to evaluate the individual and combined effects of Working Memory (WM) training and repetitive Transcranial Magnetic Stimulation (rTMS) on WM performance and smoking behaviors as well as critical mediators of these effects. These aims will be examined in a sample of tobacco dependent adults (N=130) utilizing a 2x2 factorial experimental design including four groups (WMT+rTMS, sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS.

Read the detailed description

SPECIFIC AIMS Smoking remains the leading cause of preventable death in the U.S. Current first line treatments leave approximately 70% of tobacco dependent individuals unsuccessful in their attempt to quit. Specifically, only 5-30% of those who initiate treatment, including intensive first-line interventions, are able to maintain abstinence for one or more years. The inability to quit despite motivation to do so is thought to result, in part, from self-control failure and can be understood within the framework of dual process models of addiction. Dual process models view vulnerability to tobacco dependence as the relative balance between automatic impulses and control processes orchestrated through the interplay of multiple executive function. Working memory (WM) is an executive function associated with updating information to solve immediate problems, and achieve current goals. WM is a key cognitive process underlying the regulatory control component of dual process models and is involved in the initiation, maintenance, and relapse stages of tobacco dependence. Most notably, deficits in WM performance and activation in associated brain regions predict time to relapse and strong WM has been shown to reduce the effect of craving on the ability to resist smoking. Given this relationship, individuals with tobacco dependence are likely to benefit from interventions that strengthen WM. Recently, several studies have demonstrated that increasing WM capacity through WM training (WMT) is associated with positive outcomes in several populations with substance use or impulse control disorders. Specifically, studies have demonstrated that WMT is associated with decreased: delay discounting in substance users, weight re-gain after a weight loss program, and alcohol use in heavy drinkers.

A second emerging innovation in the treatment of addictions is repetitive Transcranial Magnetic Stimulation (rTMS), a procedure which sends magnetic pulses through the scalp to stimulate neuronal tissue resulting in observed changes in neuronal plasticity and striatal dopamine. rTMS has now demonstrated positive effects in several substance use disorders including nicotine, alcohol, and stimulant dependence. This procedure has been shown to be effective in reducing smoking urges in abstinent as well as satiated smokers and to reduce cigarette consumption. While promising results for this treatment have been demonstrated, the size and durability of the therapeutic effect may be limited. Additionally, the mechanism by which rTMS exerts positive effects on smoking outcomes is unknown. Recently it has been posited that changes in WM performance resulting from rTMS may be the key pathway to its observed effects on smoking related outcomes, and furthermore that WMT administered in close temporal precedence to rTMS may result in an additive or supra-additive effect in treating addictive processes. However, these hypotheses have not been tested to date despite their importance for understanding and improving the clinical impact of these emerging therapeutic modalities for treating addictive behaviors. Interventions with the ability to effectively target self-control processes fill in a critical gap in currently available treatment options.

The primary objective of the proposed study is to evaluate the potential for improved effects and examine mediating pathways of WMT in combination with rTMS on a laboratory based smoking task and neuropsychological measures of WM performance. These aims will be examined in a sample of tobacco dependent adults (N=130) utilizing a 2x2 factorial design including four groups (WMT+rTMS, sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS. The study will include a baseline laboratory assessment, 10 WMT sessions over two weeks, followed by 10 days of WMT immediately preceding and following brain stimulation sessions (10 Hz rTMS, 2000 pulses per session, applied to left DLPFC). Neurocognitive and psychological mediators will be assessed between baseline and final laboratory assessment. Lastly, a follow-up assessment will occur one-month after the final laboratory visit. The proposed study will test the following Specific Aims:

Aim 1: To test the potential for improved effects of combining WMT with rTMS on smoking behaviors as compared to the independent effects of either condition alone. Hypothesis: Single active conditions (WMT+sham rTMS and sham WMT+rTMS) will result in significant increases in time to lapse on an analogue task as compared to the double sham condition (sham WMT+sham rTMS), and the WMT+rTMS condition will result in significant increases in time to lapse as compared to the single active conditions.

Aim 2: To test the potential for improved effects of combining WMT with rTMS on WM performance.

Hypothesis: WMT + rTMS will result in significant increases in WM performance as compared to all other conditions, including the additive increases in conditions outlined in Aim 1.

Aim 3: To test mediating pathways of the effects rTMS on smoking behaviors including changes in craving, mood, and WM performance. Hypothesis: The direct effect of rTMS on smoking outcomes will be mediated by gains in WM performance, and this effect will be largest in the WMT+rTMS condition.

Being tested
Working Memory Training, Sham Working Memory Training, repetitive Transcranial Magnetic Stimulation, Sham repetitive Transcranial Magnetic Stimulation
Medical subject headings
Tobacco Use Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Working Memory TrainingOther

    Also called Executive Function Training

    The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.

  • Sham Working Memory TrainingOther

    Also called Sham Executive Function Training

    In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.

  • repetitive Transcranial Magnetic StimulationDevice

    Also called Neuromodulation

    The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard "F3" location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application.

  • Sham repetitive Transcranial Magnetic StimulationDevice

    Also called Sham Neuromodulation

    Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.

Study groups in NCT03337113
Study groupRoleWhat they receive
WMT + rTMSExperimentalWMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
Receives: Other: Working Memory Training; Device: repetitive Transcranial Magnetic Stimulation
Sham WMT + rTMSActive comparatorSham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
Receives: Other: Sham Working Memory Training; Device: repetitive Transcranial Magnetic Stimulation
WMT + sham rTMSActive comparatorWMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
Receives: Other: Working Memory Training; Device: Sham repetitive Transcranial Magnetic Stimulation
Sham WMT + sham rTMSSham comparatorsham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
Receives: Other: Sham Working Memory Training; Device: Sham repetitive Transcranial Magnetic Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Lapse on a Smoking Lapse Analogue Task

    The Delay to Smoking Analogue Task is a behavioral choice paradigm that is sensitive to smoking medication effects in which participants earn monetary rewards for delaying initiation of cigarette smoking in 5-minute increments over a 50-minute period, following 3-hours of observed smoking deprivation. Range = 0 - 50 minutes. Higher scores indicate better ability to delay smoking.

    Measured: an average of 30 days after baseline

  2. Working Memory Performance 1

    NIH Examiner N-back score. The minimum value is 0 and maximum is 90, higher scores indicate a better outcome. Calculated change scores are presented (outcome score at day 30 minus baseline score).

    Measured: Change from baseline score to score at 30 days

  3. Working Memory Performance 2

    NIH Examiner Dot Counting Task score. The minimum total score is 0 and the maximum score is 27, higher scores indicate a better outcome. Calculated change scores are presented (outcome score at day 30 minus baseline score).

    Measured: Change from baseline score to score at 30 days

  4. Working Memory Performance 3

    Mean End Level Score on Maastricht University Working Memory Tasks. For each scale (i.e. visuospatial, back-digit, and letter-sequencing) the minimum total is 3 and the maximum is 15, higher scores indicate a better outcome.

    Measured: Change from baseline score to score at 30 days

  5. Cigarette Consumption

    Self reported number of cigarettes smoked daily

    Measured: throughout 60 day study participation, cigarettes per day assessed at outcome reported

Secondary outcomes (2)
  1. Delay Discounting

    Discounting Rate on the Monetary Choice Questionnaire, assessed by k (log transformed). Individuals made hypothetical choices between smaller immediate rewards (e.g. $11 today) and larger delayed rewards (e.g. $30 in 7 days) at varying levels of hyperbolic-like discounting. Overall temporal discounting function (k) was assessed; larger values indicate steeper discounting which reflects a worse outcome.

    Total score range = 0 - 0.25.

    Measured: Change from baseline score to score at 30 days

  2. Cigarette Demand

    Demand characteristics on the Cigarette Purchase Task. Demand sensitivity indicates sensitivity to change in price, with higher values reflecting higher sensitivity to the monetary reinforcer rather than the substance, thus higher scores reflect a better outcome. Score range = 0 - .100.

    Measured: Change from baseline score to score at 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2017
  2. Study start5 Mar 2018
  3. Primary completion31 Jan 2021
  4. Study completion31 Jan 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
A 2x2 factorial model will include four groups (Working Memory Training \[WMT\] + repetitive Transcranial Magnetic Stimulation \]rTMS\], sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS on the primary outcome variables.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03337113
Sponsor's protocol ID
1705-003
Status last verified
Apr 2022
First submitted
25 Oct 2017
Last updated
2 May 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided: IPD may be shared.

Publications

  • Lechner WV, Philip NS, Kahler CW, Houben K, Tirrell E, Carpenter LL. Combined Working Memory Training and Transcranial Magnetic Stimulation Demonstrates Low Feasibility and Potentially Worse Outcomes on Delay to Smoking and Cognitive Tasks: A Randomized 2 x 2 Factorial Design Pilot and Feasibility Study. Nicotine Tob Res. 2022 Nov 12;24(12):1871-1880. doi: 10.1093/ntr/ntac183.

    PubMed 35907262

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Working Memory Training and repetitive Transcranial Magnetic Stimulation in people with Tobacco Use Disorder, run by Kent State University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 May 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Lapse on a Smoking Lapse Analogue Task (time frame: an average of 30 days after baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03337113, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in